Clostridium difficile colitis.
暂无分享,去创建一个
C. Pothoulakis | C. Kelly | J. Lamont | Ciaran P. Kelly | Charalabos Pothoulakis | J. Lamont | J. Lamont
[1] R Sedivy,et al. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. , 1995, The Journal of clinical investigation.
[2] C. Surawicz,et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. , 1994, JAMA.
[3] A. Glatt,et al. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] C. Pothoulakis,et al. Clostridium difficile-associated diarrhea and colitis: pathogenesis and therapy. , 1993, International journal of antimicrobial agents.
[5] Esther Jacobowitz Israel,et al. Diminished Clostridium difficile toxin A sensitivity in newborn rabbit ileum is associated with decreased toxin A receptor. , 1992, The Journal of clinical investigation.
[6] L. Peterson,et al. Treatment of Asymptomatic Clostridium difficile Carriers (Fecal Excretors) with Vancomycin or Metronidazole , 1992, Annals of Internal Medicine.
[7] G. Doern,et al. Laboratory diagnosis of Clostridium difficile-associated gastrointestinal disease: comparison of a monoclonal antibody enzyme immunoassay for toxins A and B with a monoclonal antibody enzyme immunoassay for toxin A only and two cytotoxicity assays , 1992, Journal of Clinical Microbiology.
[8] K.,et al. Multicenter evaluation of a new enzyme immunoassay for detection of Clostridium difficile enterotoxin A , 1992, Journal of clinical microbiology.
[9] N. Schupf,et al. Reduction in the incidence of Clostridium difficile-associated diarrhea in an acute care hospital and a skilled nursing facility following replacement of electronic thermometers with single-use disposables. , 1992, Infection control and hospital epidemiology.
[10] D. Conwell,et al. Development of a rapid enzyme immunoassay for Clostridium difficile toxin A and its use in the diagnosis of C. difficile-associated disease , 1991, Journal of clinical microbiology.
[11] T. Wilkins,et al. Identification of the latex test-reactive protein of Clostridium difficile as glutamate dehydrogenase , 1991, Journal of clinical microbiology.
[12] G. Triadafilopoulos,et al. Acute abdomen as the first presentation of pseudomembranous colitis. , 1991, Gastroenterology.
[13] C. Pothoulakis,et al. Characterization of rabbit ileal receptors for Clostridium difficile toxin A. Evidence for a receptor-coupled G protein. , 1991, The Journal of clinical investigation.
[14] W. Stamm,et al. Correlation of immunoblot type, enterotoxin production, and cytotoxin production with clinical manifestations of Clostridium difficile infection in a cohort of hospitalized patients , 1991, Infection and immunity.
[15] C. Pothoulakis,et al. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. , 1991, The Journal of pediatrics.
[16] L. Peterson,et al. Nosocomial Clostridium difficile colonisation and disease , 1990, The Lancet.
[17] C. Pothoulakis,et al. Macrophage-dependent stimulation of T cell-depleted spleen cells by Clostridium difficile toxin A and calcium ionophore. , 1990, Cellular immunology.
[18] L. Peterson,et al. Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. , 1990, The American journal of medicine.
[19] S. Borriello. The influence of the normal flora on Clostridium difficile colonisation of the gut. , 1990, Annals of medicine.
[20] C. Surawicz,et al. Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. , 1989, The American journal of gastroenterology.
[21] J. Rask-Madsen,et al. BACTERIOTHERAPY FOR CHRONIC RELAPSING CLOSTRIDIUM DIFFICILE DIARRHOEA IN SIX PATIENTS , 1989, The Lancet.
[22] W. Stamm,et al. Nosocomial acquisition of Clostridium difficile infection. , 1989, The New England journal of medicine.
[23] C. Pothoulakis,et al. Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers. , 1988, The Journal of clinical investigation.
[24] C. Pothoulakis,et al. Clostridium difficile toxin A stimulates intracellular calcium release and chemotactic response in human granulocytes. , 1988, The Journal of clinical investigation.
[25] K. Wilson,et al. Acquisition of Clostridium difficile from the hospital environment. , 1988, American journal of epidemiology.
[26] D. Weaver,et al. Surgical management of pseudomembranous colitis. , 1988, The American surgeon.
[27] D. Kleinfeld,et al. Parenteral therapy for antibiotic-associated pseudomembranous colitis. , 1988, The Journal of infectious diseases.
[28] T. Wilkins,et al. Clostridium difficile: its disease and toxins , 1988, Clinical Microbiology Reviews.
[29] C. Kelly,et al. An epidemic of pseudomembranous colitis: importance of person to person spread. , 1987, Gut.
[30] M. O'brien,et al. Differential effects of Clostridium difficile toxins A and B on rabbit ileum. , 1987, Gastroenterology.
[31] J. Silva,et al. Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin. , 1987, Journal of clinical gastroenterology.
[32] R. Bolton,et al. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. , 1986, Gut.
[33] J. Bartlett,et al. IS CLOSTRIDIUM DIFFICILE ENDEMIC IN CHRONIC-CARE FACILITIES? , 1986, The Lancet.
[34] G. Young,et al. Antibiotic-associated colitis: why do patients relapse? , 1986, Gastroenterology.
[35] D. Gordon,et al. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. , 1985, The American journal of gastroenterology.
[36] D. Gerding,et al. PROSPECTIVE RANDOMISED TRIAL OF METRONIDAZOLE VERSUS VANCOMYCIN FOR CLOSTRIDIUM-DIFFICILE-ASSOCIATED DIARRHOEA AND COLITIS , 1983, The Lancet.
[37] R. Yolken,et al. Serum antibody response to toxins A and B of Clostridium difficile. , 1983, The Journal of infectious diseases.
[38] I. Hill,et al. Epidemiology of Clostridium difficile in infants. , 1982, The Journal of infectious diseases.
[39] F. Tedesco,et al. Rectal sparing in antibiotic-associated pseudomembranous colitis: a prospective study. , 1982, Gastroenterology.
[40] Tedesco Fj. Treatment of recurrent antibiotic-associated pseudomembranous colitis. , 1982 .
[41] J. Silva,et al. Epidemiology of antibiotic-associated colitis; isolation of Clostridium difficile from the hospital environment. , 1981, The American journal of medicine.
[42] M. Keighley,et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. , 1978, British medical journal.
[43] Kreutzer Ew,et al. Treatment of antibiotic-associated pseudomembranous colitis with cholestyramine resin. , 1978, The Johns Hopkins medical journal.
[44] F. Tedesco,et al. ORAL VANCOMYCIN FOR ANTIBIOTIC-ASSOCIATED PSEUDOMEMBRANOUS COLITIS , 1978, The Lancet.
[45] A. Price,et al. CLOSTRIDIUM DIFFICILE AND THE ÆTIOLOGY OF PSEUDOMEMBRANOUS COLITIS , 1978, The Lancet.
[46] J. Bartlett,et al. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. , 1978, The New England journal of medicine.
[47] J. Parry,et al. Undescribed toxin in pseudomembranous colitis. , 1977, British medical journal.
[48] R. Barton,et al. Clindamycin-associated colitis. A prospective study. , 1974, Annals of internal medicine.
[49] I. C. Hall,et al. INTESTINAL FLORA IN NEW-BORN INFANTS: WITH A DESCRIPTION OF A NEW PATHOGENIC ANAEROBE, BACILLUS DIFFICILIS , 1935 .
[50] C. Pothoulakis,et al. Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding. , 1992, Gastroenterology.
[51] S. Tabaqchali,et al. Epidemiologic markers of Clostridium difficile. , 1990, Reviews of infectious diseases.
[52] L. Briceland,et al. Multidisciplinary cost-containment program promoting oral metronidazole for treatment of antibiotic-associated colitis. , 1988, American journal of hospital pharmacy.